

INTERVIEW SUMMARY

Applicant thanks Examiner Kam for taking time from her duties to meet by telephone with Applicant's attorney on 3 September 2008 and again on 18 September 2008.

(A) a brief description of the nature of any exhibit shown or any demonstration conducted;

N/A

(B) identification of the claims discussed;

Claims 15 and 26 as they relate to diabetic ulcers.

(C) identification of specific prior art discussed;

U.S. Patent No. 7,323,443 for double patenting.

(D) identification of the principal proposed amendments of a substantive nature discussed, unless these are already described on the Interview Summary form completed by the examiner;

Proposed claim amendments are to amend the claims to be directed to diabetic ulcer treatment, to amend the claims to specifically recite in the body of the claim that the treatment is for an individual with diabetic ulcers and to cancel claim 15.

(E) the general thrust of the principal arguments of the applicant and the examiner should also be identified, even where the interview is initiated by the examiner. The identification of arguments need not be lengthy or elaborate. A verbatim or highly detailed description of the arguments is not required. The identification of the arguments is sufficient if the general nature or thrust of the principal arguments can be understood in the context of the application file. Of course, the applicant may desire to emphasize and fully describe those arguments which he or she feels were or might be persuasive to the examiner;

Applicant will be further distinguished from the prior art of record by modifying the claims to include the treatment of diabetic ulcers and to specify in the body of the claim that the subject has a diabetic ulcers. Examiner Kam's provisional search for diabetic ulcer treatment by lactoferrin returned no relevant prior art and the Applicants believe that there is none.

(F) a general indication of any other pertinent matters discussed;

Claims were discussed in relation to amendments to include the treatment of diabetic ulcers. A specific claim amendment to the body of the claim to the treatment of subjects suffering from a diabetic ulcer was also discussed. Examiner Kam also requested a copy of the paper on the clinical trials of lactoferrin to treat diabetic ulcers which is submitted herewith in an Information Disclosure Statement.

(G) if appropriate, the general results or outcome of the interview; and

Examiner Kam and the Applicant provisionally agreed that with the addition of diabetic ulcers, the claims were novel over the prior art. Applicants again thank the Examiner for her time and the suggested claim clarification language incorporated into the amendments herein .

(H) in the case of an interview via electronic mail, a paper copy of the Internet e-mail contents MUST be made and placed in the patent application file as required by the Federal Records Act in the same manner as an Examiner Interview Summary Form, PTOL 413, is entered.

N/A